IBS Market Snap Shot

MIDDLE EAST=SAUDI+LEBANON+KUWAIT+JORDAN

Middle East – Q3 04 (MAT) - Relative Market Sizes Mkt : $ 1.56 bio; Growth MAT 04 : 10%

8783

29

22 20 20 21

14 139

6 5 4 3 1

97

88

36

27

22 22 2116

129

6 5 5 3 1

15%

9%

28%

33%

12% 12%11%

16%

(1%)0% (0%) (1%)

0%

15%

0.0

20.0

40.0

60.0

80.0

100.0

120.0

NSAIDA/H

ypChol

ARBIB

S

Atopic

Der

m

Asthm

a

A/Epil

Osteo

A/Psy

ch

A/Vira

ls

A/Fung

M/R

el

A/Par

kAlz

(5%)

0%

5%

10%

15%

20%

25%

30%

35%

2003

MAT 04

Grth 04

Middle East – Q3 04 (MAT) – IBSMkt : $ 21.9 mio; Growth MAT 04 : 12%

20.9%

10.0%8.8%

5.5%

0.0%

19.6%

8.9%9.7%

5.2%

0.5%

17.8%

9.4%8.6%

5.9%

1.9%

0%

5%

10%

15%

20%

25%

Duspatalin Buscopan Duphalac Dulcolax Zelmac

2002 2003 MAT 04

Middle East - MAT Q3 04 (Pvt) - Relative Market Importance

59%

42%

47%44%

65%

77%

57%

6% 7% 6% 7% 6% 4%7%

19%

38%35%

32%

12%

6%

23%

5%3% 3% 3% 4% 3% 5%

11% 10% 9%

14% 14%10% 10%

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

Market AHD ARB Chol NSAID ATOP IBS

KSA Jordan Lebanon Kuwait UAE

Middle East - Q3 04 (MAT) - Zelmac

0.0% 0.0% 0.0% 0.0%0.4%

0.0% 0.0%

0.9%

0.0%

2.7%

0.5% 0.6%

3.7%

0.0%

7.7%

0%

1%

2%

3%

4%

5%

6%

7%

8%

9%

KSA Jordan Lebanon Kuwait UAE

2002 2003 MAT 04

Middle East - Q3 04 (MAT) - Zelmac

0.0% 0.0% 0.0% 0.0%0.4%

0.0% 0.0%

0.9%

0.0%

2.7%

0.5% 0.6%

3.7%

0.0%

7.7%

0%

1%

2%

3%

4%

5%

6%

7%

8%

9%

KSA Jordan Lebanon Kuwait UAE

2002 2003 MAT 04